Based on strong preclinical evidence of their efficacy and tolerability, an abundance of clinical trials are currently testing co-administration of OVs and PD-1/PD-L1 ICIs in cancer patients (ClinicalTrials.gov trials: NCT06196671, NCT05122572, NCT05222932, NCT05346484, and NCT02798406). Here, CD274 is linked to cancer.